Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nordic Bioscience
Biotech
Lilly pays $55M for rights to KeyBioscience’s diabetes assets
Eli Lilly is paying $55 million upfront for the rights to KeyBioscience’s pipeline of treatments for Type 2 diabetes and other metabolic conditions.
Nick Paul Taylor
Jun 8, 2017 8:34am
KeyBioscience taps Enteris to create oral metabolic peptide
Jan 26, 2017 5:20am